Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Breast 2Thoracic 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Breast Neoplasms 2Breast Neoplasms, Male 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Drug Screening Assays, Antitumor × Breast × Clear all
NCT05833802 2023-04-27

Computation Prediction of Drug Response Based on Omics Data

Peking University Cancer Hospital & Institute

Unknown
25 enrolled
Breast

Breast Neoplasms

NCT00003253 2013-12-19

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡